YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model
Authors:
Open Access
- 3 March 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Abstract
YKL-40 is a glycoprotein that has been extensively studied due to its elevated expression in numerous solid tumors, and its expression is altered in melanoma, where its levels in tumor tissues are notably lower compared with those in normal skin tissues. Patients with melanoma exhibiting high YKL-40 expression have improved survival rates, suggesting a potential tumor-suppressive function of YKL-40 in melanoma. The present investigation into the ectopic expression of YKL-40 in human (A375) and murine (B16F10) melanoma cell lines demonstrated a consequential decrease in cell proliferation, migration and invasion. Furthermore, YKL-40 overexpression was associated with suppressed tumor growth in a subcutaneous melanoma mouse model and diminished tumor cell metastasis in a pulmonary metastasis model. RNA-sequencing analysis revealed that YKL-40 overexpression led to the upregulation of immune cell infiltration-related signaling pathways, including cytokine receptor interactions, natural killer cell-mediated cytotoxicity, and T and B lymphocyte receptor signaling. These findings highlight the potential of YKL-40 as a regulator of tumor-immune interactions in melanoma, highlighting its prospective utility in immunotherapy-based treatment strategies for melanoma.Keywords
All Related Versions
Funding Information
- Shandong Provincial Natural Science Foundation (ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146, ZR2020MH146)
This publication has 55 references indexed in Scilit:
- The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancerImmunity, 2023
- YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancerCancer Letters, 2023
- Targeted Therapy and Immunotherapy in MelanomaDermatologic Clinics, 2022
- Treatment of Advanced Melanoma in 2020 and BeyondJournal of Investigative Dermatology, 2021
- Measured and genetically predicted plasma YKL-40 levels and melanoma mortalityEuropean Journal of Cancer, 2019
- Macrophages, innate immunity and cancer: balance, tolerance, and diversityCurrent Opinion in Immunology, 2010
- Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanomaCancer, 2006
- Expression of YKL-40 by peritumoral macrophages in human small cell lung cancerLung Cancer, 2005
- Absent or low expression of T-cell receptor ζ-chain in T cells infiltrating human pathological skin conditionsArchives of Dermatological Research, 2002
- T cell development in mice lacking the CD3‐zeta/eta gene.The EMBO Journal, 1993